Search Results - "Ceulemans, Rob"

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation by Hodkinson, Brendan P., Schaffer, Michael, Brody, Joshua D., Jurczak, Wojciech, Carpio, Cecilia, Ben-Yehuda, Dina, Avivi, Irit, Forslund, Ann, Özcan, Muhit, Alvarez, John, Ceulemans, Rob, Fourneau, Nele, Younes, Anas, Balasubramanian, Sriram

“…•Biomarkers of response to ibrutinib + nivolumab were analyzed in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma and Richter transformation.•DLBCL…”
Get full text

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study by Younes, Anas, Brody, Joshua, Carpio, Cecilia, Lopez-Guillermo, Armando, Ben-Yehuda, Dina, Ferhanoglu, Burhan, Nagler, Arnon, Ozcan, Muhit, Avivi, Irit, Bosch, Francesc, Caballero Barrigón, Maria Dolores, Hellmann, Andrzej, Kuss, Bryone, Ma, David D F, Demirkan, Fatih, Yağci, Münci, Horowitz, Netanel A, Marlton, Paula, Cordoba, Raul, Wrobel, Tomasz, Buglio, Daniela, Streit, Michael, Hodkinson, Brendan P, Schaffer, Michael, Alvarez, John, Ceulemans, Rob, Balasubramanian, Sriram, de Jong, Jan, Wang, Shean-Sheng, Fourneau, Nele, Jurczak, Wojciech

“…Preclinical studies have shown synergistic antitumour effects between ibrutinib and immune-checkpoint blockade. The aim of this study was to assess the safety…”
Get full text

Abstract 4024: Phase 1/2a LYM1002 study of ibrutinib (ibr) + nivolumab (nivo): Exome and gene expression profiling (GEP) analyses by histology and responder status by Hodkinson, Brendan, Schaffer, Michael, Brody, Joshua, Jurczak, Wojciech, Carpio, Cecilia, Ben-Yehuda, Dina, Avivi, Irit, Saleem, Rao, Özcan, Muhit, Alvarez, John, Ceulemans, Rob, Fourneau, Nele, Balasubramanian, Sriram, Younes, Anas

“…Abstract A phase 1/2a study (LYM1002 [EudraCT 2014-005191-28]) of ibr (560 mg once daily) + nivo (3 mg/kg on a 14-day cycle) demonstrated acceptable safety and…”
Get full text

Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia by Younes, Anas, Brody, Joshua, Carpio, Cecilia, Lopez-Guillermo, Armando, Ben-Yehuda, Dina, Ferhanoglu, A. Burhan, Nagler, Arnon, Ozcan, Muhit, Avivi, Irit, Bosch Albareda, Francesc, Caballero Barrigón, María Dolores, Masood, Aisha, Streit, Michael, Alvarez, John, Ceulemans, Rob, Kharabi Masouleh, Behzad, Balasubramanian, Sriram, Schaffer, Michael, Wang, Shean-Sheng, Fourneau, Nele, Jurczak, Wojciech

“…Background: Preclinical studies have demonstrated synergistic antitumor activity when immune checkpoint inhibitors targeting the programmed cell death…”
Get full text